Q4 2020

Source filing unavailable

Q4 2020 · —

derived · Computed from the longer spans the company filed.

Revenue—

Net Income

-$42.86M

derivedN/M vs Q4 2019

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Incomederived-$47,330,000N/M

Operating Cash Flowderived

Same quarter

Metric	Q4 2020derived from reported figures	Q4 2019derived from reported figures	Q4 2018
Revenue	—	$309.00K	$296.00K
Net Income	-$42.86M	-$40.94M	-$20.65M
EPS Diluted	—	—	-$0.52

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR